Agyany Pharma LTD

Startseite
Schweiz
Zug
Agyany Pharma LTD

Pioneering Breakthroughs in Gene Based Parkinson's Disease Treatment.

15/09/2025

"🌍 Genetics Matter—And So Does Geography
The prevalence of neuronopathic Gaucher disease (nGD) in East Asia highlights the urgent need for region-specific medical strategies.

While Western populations predominantly present with non-neuronopathic forms, Eastern populations are more often affected by the severe neuronopathic types.

At Agyany Pharmaceuticals, we believe precision medicine means addressing the true needs of diverse populations, wherever they are.

"

10/09/2025

"🌏 Spotlight on Rare Diseases in Asia
Neuronopathic Gaucher Disease (nGD) is considered rare worldwide—but in parts of Asia, its prevalence is significantly higher. This regional disparity demands focused awareness, early screening, and dedicated research.

At Agyany Pharmaceuticals, we are committed to advancing diagnostics and potential therapies for overlooked rare diseases like nGD—especially where the need is greatest.

Because rare doesn’t mean irrelevant.

"

06/09/2025

Rethinking Diabetes Treatment: Ambroxol’s Emerging Role
Originally developed as a respiratory therapy, Ambroxol is gaining attention in an entirely new space—type 2 diabetes.

🧪 A recent study reveals Ambroxol enhances NEU1 expression, which activates insulin receptors and improves insulin sensitivity in preclinical models.

At Agyany Pharmaceuticals, we’re exploring this novel axis between lysosomal biology and metabolic disease. Could this long-standing molecule be repurposed for a modern metabolic challenge?

We believe the science speaks for itself—and it’s time to listen.

03/09/2025

New Scientific Insight: NEU1 & Ambroxol in Insulin Sensitivity

Recent findings reveal that Neuraminidase 1 (NEU1) is essential in activating insulin receptors. Fascinatingly, Ambroxol—a commonly used mucolytic—can stimulate NEU1 activity, reversing insulin resistance and normalizing glucose levels in obese mice.

At Agyany Pharma, we're investigating how this emerging mechanism could reshape type 2 diabetes treatment. NEU1 modulation may unlock a new therapeutic frontier in metabolic disease.

🔬 | | | | |

26/08/2025

🧠 Did you know nearly 50% of Parkinson’s disease clinical trials now focus on disease-modifying therapies—yet not one has secured regulatory approval?
A new review by Koros et al. sheds light on why progress has stalled and where hope lies. Promising strategies include:
✔️ Targeting alpha-synuclein aggregation
✔️ Boosting cellular degradation pathways
✔️ Leveraging novel gene-editing techniques
This research pushes the frontier toward truly transformative therapies.
ParkinsonsAwareness

20/08/2025

Parkinson’s disease research is evolving rapidly. A major breakthrough lies in targeting alpha-synuclein, a key protein linked to the disease's progression.
🔬 Koros et al. outline promising therapies:
• Immunotherapy – Using antibodies to clear misfolded proteins
• Anti-aggregation compounds – Preventing toxic clumping
• Gene therapy – Employing CRISPR to reduce production

As we move toward precision neurology, these innovative strategies offer renewed hope for disease-modifying treatments

15/08/2025

Ambroxol: A Step Forward in Parkinson Disease Dementia Research: A recent randomized clinical trial explored Ambroxol as a potential treatment for Parkinson Disease Dementia (PDD). While the study found Ambroxol to be safe and well-tolerated, and it successfully increased ẞ-glucocerebrosidase levels (a key target), its effect on cognition wasn't definitively confirmed. This research is vital for informing larger trials and continues to advance our understanding of PDD.

13/08/2025

Did you know that early signs of Parkinson’s are: the loss of smell of foods like bananas, dill pickles and licorice.

09/08/2025

Happy Birthday to Arndt Rolfs our Visionary Leader!

On behalf of all your colleagues at Agyany, we wish you a truly joyful birthday! You are our visionary and inspiring leader, whose guidance and ambition fuel both innovation and unity within our team.

Your transformative leadership and unwavering commitment inspire us daily. Thank you for steering our company toward new horizons with clarity and purpose.

Here’s to celebrating you today and to many more milestones together!
Wishing you continued success, health, and happiness.

05/08/2025

"Did you know?
An early sign of Parkinson’s Disease is a noticeable change in handwriting — especially if it becomes smaller or more crowded over time. Recognizing subtle changes can lead to earlier diagnosis and better management.

At Agyany Pharma, we are committed to advancing and for through groundbreaking research in and ."

21/07/2025

📚 Clinical Case Update: Long-Lasting Ambroxol Response in GD Type 2
We’d like to highlight a recent case report by Kanako Higashi et al., titled:
🧠 “Rapid and long‐lasting efficacy of high‐dose ambroxol therapy for neuronopathic Gaucher disease”
This report describes a female patient with GD Type 2, carrying p.L483P and p.R502H mutations in the GBA1 gene, who began a combined treatment with imiglucerase and ambroxol.
🔬 Remarkably, her motor activity improved within 1 week, and the neuroprotective benefits continued for over 30 months, showcasing the potential of ambroxol as a pharmacological chaperone in neuronopathic GD.
🔗 Read the full article

18/07/2025

🚀 Agyany Pharma at the 2nd GBA1 Meeting – Montreal, Canada 🇨🇦

From June 5–7, 2025, our team proudly participated in the 2nd GBA1 Meeting, hosted by McGill University. The event brought together leading academic and industry partners dedicated to advancing GBA1-related research and therapies.

We were thrilled to engage with fellow researchers, explore collaborative opportunities, and further our mission to develop efficient treatments for individuals affected by GBA1 mutations.

💡 Collaborative science is the future — and we’re just getting started.

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag , hashtag , hashtag , hashtag .

Adresse

Chamerstrasse 176
Zug
6300

Webseite

https://www.agyanypharma.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Agyany Pharma LTD erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.